Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

45.52 +0.09 (+0.20%)

Streaming Delayed Price Updated: 3:59 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

33 34 Next >

BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Recession Fears are Creating a Golden Opportunity for Biotech Stocks ↗

April 08, 2022

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.

Via InvestorPlace

How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug ↗

April 08, 2022

Only Medicare patients enrolled in specific studies will receive reimbursement.

Via Investor's Business Daily

Good and Bad stock news ↗

April 05, 2022

Microsoft is down because of an FTC investigation of its possible anti-competitive moves.

Via Talk Markets

Why Are ImmunoGen Shares Trading Lower Today ↗

March 21, 2022

ImmunoGen Inc (NASDAQ: IMGN)

Via Benzinga

New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

April 04, 2022

From Genentech

Via Business Wire

SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio ↗

April 04, 2022

Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC: SFTBY) (OTC: SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S....

Via Benzinga

Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis ↗

April 04, 2022

Via Benzinga

FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults ↗

April 04, 2022

Via Benzinga

U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults

April 04, 2022

From Genentech

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial ↗

March 30, 2022

Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)

Via Benzinga

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer

March 30, 2022

From Genentech

Via Business Wire

Biotech Funds and ETFs Continue to Lag ↗

March 28, 2022

It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...

Via Talk Markets

Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗

March 25, 2022

Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,

Via Benzinga

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗

March 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Flood Helping Ukraine ↗

March 24, 2022

Emerging markets are gaining as mature markets look risky.

Via Talk Markets

How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag ↗

March 24, 2022

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

Via Investor's Business Daily

Up On Bad News ↗

March 22, 2022

Despite the plane crash in China, Boeing's stock is up today.

Via Talk Markets

World Markets News For Friday ↗

March 18, 2022

Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.

Via Talk Markets

Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population ↗

March 16, 2022

Via Benzinga

Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing ↗

March 16, 2022

If approved, this would be the company's second drug to hit the U.S. market.

Via Investor's Business Daily

New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)

March 16, 2022

From Genentech

Via Business Wire

The OTCQX's Top 10 Experience A Shuffle In February ↗

March 15, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

Hopes For A Peace Accord ↗

March 14, 2022

The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.

Via Talk Markets

Biogen Posts New Updates Across its Spinraza SMA Research Program ↗

March 14, 2022

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and...

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.